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The need to understand the mechanism of gastric secretion in order 
to help patients with peptic ulcer disease brought surgeons to the study 
of gastrointestinal physiology early in the history of the field. Three 
main agents cause fundic parietal cells to secrete acid: vagal stimulation, 
gastrin, and histamine. The action of each can be manipulated and blocked, 
and the interdependence among them has therapeutic potential. The 
experimental counterpart of the Zol1inger-El1ison syndrome was created 
surgically in dogs, producing hypergastrinemia and gastric hypersecretion. 
The effect of parietal cell histamine-2 receptor blockade with metiamide 
on the subsequent development of ulcers was studied using a controlled, 
cross-over design. 




REVIEW: MAJOR AGONISTS OF GASTRIC SECRETION 
I. Vagal Stimulation 
In 1814 Sir Benjamin Brodie was perhaps first to observe that vagal 
nerve stimulation evoked gastric secretion of acid (55). In 1858, Claude 
Bernard observed that section of the vagus in animals resulted in decreased 
gastric secretion and impaired gastric contraction (55). Surgical treatment 
of peptic ulcer during the late 1800's remained limited to gastrointestinal 
resection and anastomosis. In January, 18815 Billroth completed the first 
successful pylorectomy for cancer with the anastomosis named for him. In 
November, 1881, von Rydygier performed the first gastrectomy for peptic 
ulcer. 
At the turn of the century the classic experiments of Pavlov 
documented anew the gastric secretory response to vagal stimulation by 
sham-feeding, and its disappearance after vagotomy. Vagotomy in humans by 
the abdominal route was introduced in the early 1900's, for a variety of 
conditions. The role of vagotomy in the treatment of peptic ulcer was 
little appreciated until, in 1943, Dragstedt and Owens published their 
findings in this regard (29). Dragstedt had observed that patients with 
duodenal ulcer showed excessive secretion of gastric juice at night and in 
response to food, and tested his hypothesis that vagal hypertonia might 
be the cause by performing transthoracic vagotomy in two patients with 
duodenal ulcer. Both experienced a dramatic fall in volume and concentration 
of gastric acid secretion, with amelioration of symptoms. Further reports 
from Dragstedt (27) and others followed, confirming his results. Much of 
what we now know about gastric physiology came with the surge of interest 
created by his work. 
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Vagal stimulation comprises the "cephalic phase" of gastric secretion, 
and has three effects: 1) it directly stimulates the parietal cell to 
secrete acid; 2) it stimulates cells in the gastric antrum to release 
gastrin into the blood, which in turn acts on parietal cells to produce 
acid; and 3) it exerts an important permissive or facilitating effect on 
gastric secretion, probably at the parietal cell level, which increases 
fundic sensitivity to stimuli for acid secretion (86). 
All these functions are blocked by vagotomy. Changes in gastric 
secretion after surgical or pharmacological vagotomy have been amply 
documented. Surgical vagotomy (truncal, selective, or proximal gastric) 
reduces acid response to pentagastrin and histamine by 60% (110). Vagal 
block with atropine inhibits acid secretion in response to insulin 
stimulation in dogs; in increasing doses, atropine inhibits gastrin 
release in response to insulin, and in response to feeding (21). Patients 
with medical (hexamethoniurn and atropine) or surgical vagotomy show decreased 
acid response to histamine and to pentagastrin stimulation (69,86). 
It is well known and important that non-vagal stimuli for gastrin 
release will produce acid secretion in the face of vagotomy, and stimuli 
inhibiting gastrin release will counteract vagal stimulation: for example, 
acid in the duodenum inhibits gastrin release and acid secretion in response 
to insulin-induced vagal stimulation (21). 
Although the limitations of vagotomy alone for duodenal ulcer 
disease have become apparent, it remains an essential component of ulcer 
surgery. Gastric emptying is impaired with truncal or selective vagotomy. 
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so pyloroplasty, gastrojejunostomy or gastric resection is usually done. 
Emptying remains more nearly normal with highly selective vagotomy, so 
a drainage procedure is not necessary. 
II. Gastrin 
A. Discovery of Gastrin 
In 1905 Edkins administered extracts of antral mucosa intravenously 
to animals, and observed an increase in gastric secretion, securing the 
first evidence for an antral hormone mediating gastric secretion (40). In 
1948, Grossman and Ivy demonstrated humoral transmission of the distention 
stimulus for fundic acid secretion in dogs (49). 
In 1951, Dragstedt, Oberhelman, and Smith (28) demonstrated that 
when the antrum of dogs is transplanted to the colon as a diverticulum, 
gastric hypersecretion ensues, ultimately producing stomal ulcer at the 
gastrojejunostomy margin. The excess gastric secretion was attributed to 
constant release of gastrin due to antral distention and to the lack of 
acid inhibition. 
The hormone, gastrin, was finally isolated from hog antral mucosa, 
identified, and synthesized by Gregory and Tracy in 1964 (45). Measurement 
of gastrin levels by radioimmunoassay was achieved by McGuigan and Trudeau 
in 1968 (76), with later advances resulting in a more sensitive assay with 
fewer cross-reactions (115). 
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B. Nature of Gastrin 
Gastrin is contained in specific epithelial cells in the mucosa of 
the antrum. These cells are not distinguished by a particular staining 
reaction, but have been identified using fluorescein-labelled antibodies 
to gastrin (75). By electron microscopy (EM) the cells are seen to 
contain the labelled hormone in round granules in the cytoplasm (47), which 
can be recovered intact for study (33). Cells containing gastrin by 
immunofluorescence are found in the antrum, duodenum, jejunum, and ileum, 
in descending order of abundance. However, cells with the antral cell 
structure by EM are few in the duodenum and not seen in the lower small 
bowel: intestinal gastrin is probably secreted by another of the 
endocrine-like cells in the gut (94). 
The antral gastrin-containing or G-cells of rats have been shown 
to empty their granules in response to feeding, with a corresponding rise 
in serum gastrin; an hour later, more granules appear, while serum gastrin 
stays elevated (70). In dogs, antral gastrin concentration is not 
diminished by feeding (110). 
Gastrin exists in several forms (46). The original form isolated 
from hog antral mucosa was a peptide of 17 amino acids, now known as 
little gastrin or G17 (see Structure, Table 1). It is, on a molar basis, 
the most potent form, 500 times more powerful than histamine in stimulating 
acid secretion. Later, a peptide of 34 amino acids was identified, and 
called big gastrin or G34. It consists of G17 with a side chain. G17 and 
G34 exist in sulfated and unsulfated moieties, with no difference in 
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biological activity. The carboxy-terminal pentapeptide amide of G17 has 
all the biologic actions of the whole molecule (110). 
Recently a peptide of thirteen amino acids has been isolated, 
named minigastrin or G13; its function is not clear. Two more forms, of 
as yet unknown structure, have high molecular weights and are called 
big-big gastrin and Rehfeld Component I; their function is not clear; 
they are only weakly physiologically active (110). 
The concentration of gastrin in the antrum in man is five times 
that in the duodenum, though the larger mucosal area of the duodenum may 
counterbalance this (110). Antral gastrin is 95% G17. The gastrin in 
the duodenum and jejunum is 50% G34. G17 predominates in tissue, G34 in 
serum; big-big gastrin is found in fasting plasma only (89). Feeding 
releases G17 and G34. G17 has a rapid turnover, G34 a slower onset and 
offset (10). All forms are acted on by trypsin to release G17 (88,116). 
Pentagastrin is a commercially available synthetic pentapeptide 
consisting of the carboxy-terminal tetrapeptide amide of gastrin, with 
beta-alanine and an N-terminal blocking group added. Its potency is 
comparable to that of the carboxy-terminal pentapeptide amide of gastrin (110). 
C. Release of Gastrin 
A great deal was learned about the antral stimuli for release of 
gastrin before the hormone itself was identified. By 1950 Dragstedt and 
coworkers (31) had established that total antrectomy decreased acid 
secretion by 86%, while partial antrectomy had no effect; depriving the 
antrum of contact with food similarly decreased secretion; and transplanting 
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the antrum to the colon produced acid hypersecretion. They concluded 
that the gastric phase of secretion was mediated by gastrin released by the 
antrum in contact with food. In 1952, Storer and coworkers (96,97) 
observed that the Exalto-Mann-Wi11iamson procedure produced acid hyper¬ 
secretion as it produced ulcers, and that antrectomy with vagotomy was 
more effective than either procedure alone in preventing ulceration. In 
1964, the year gastrin was identified, Dragstedt and Woodward (32) wrote 
that the pathogenesis of gastric ulcer lay in antral stasis, secondary 
to vagotomy or pyloric stenosis, or in absence of antral acidification, 
secondary to surgical modification of normal anatomy; these conditions 
then produced excess gastrin release and acid secretion, resulting in 
ulcer. All these findings concerning the antral release of gastrin have 
essentially been confirmed by work utilizing gastrin assays unavailable 
then. 
Gastrin is released under physiological conditions by 1) vagal 
stimulation, 2) distention of either the pyloric or oxyntic gland area, 
and 3) antral gastrin-containing cell contact with food (8,23). 
1. Vagal Release of Gastrin 
The vagal release of gastrin in dogs was documented by 
Nilsson et al (81) among others, who sham-fed dogs with gastric fistulae 
and observed increased serum gastrin and acid secretion. Acetylcholine 
applied topically to the antrum also stimulates acid secretion in dogs, 
though this may be by nonvagal pathways (92). 
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Blockade of vagal fibers to the antrum has produced variable results. 
In Nilsson's study, atropine diminished the gastrin response to sham-feeding, 
and abolished the acid response. Tepperman (100), studying gastric 
fistula dogs, found that surgical vagotomy of the fundus and antrum 
abolished the gastrin response to insulin, and diminished the acid response. 
The vagal cholinergic pathway in many functions differently, and 
may have both stimulatory and inhibitory effects on gastrin release (36,64). 
Walsh and coworkers (36), studying normal subjects, found that atropine 
decreased acid secretion but increased the gastrin response to insulin. 
In further studies (112), atropine also increased gastrin response to 
feeding. 
Studies in humans after vagotomy (61) (truncal, selective, and 
proximal gastric) have documented increased basal gastrin in all types, 
up to 57%, attributed to loss of the inhibitory influence of acid secreted 
into the antrum. After vagotomy there is also heightened gastrin response 
to feeding, attributed to antral stasis of food stimulating constant 
gastrin release. This heightened response is less in patients who have 
had pyloroplasty, with more rapid gastric emptying (61). It is clear then 
that blockade of vagal fibers to the antrum does not decrease gastrin 
release when gastrin is stimulated by local factors (12). 
Vagal innervation may have a role in the intramural, cholinergic 
pathway thought to mediate gastrin release in response to distention, and 
possibly mediates acid secretion in response to other, non-gastrin 
excitatory or inhibitory stimuli (12,82). 
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2. Release of Gastrin by Distention 
The release of gastrin by distention of the stomach has been 
confirmed by Debas and Grossman (22), who studied dogs with gastric 
fistulae and innervated antral and oxyntic gland area pouches. They 
found that graded distention of the oxyntic pouch, with the antrum 
alkalinized, led to graded increases in serum gastrin, and in acid 
secretion. With the antrum acidified, no gastrin was secreted, and much 
less acid. They postulated that antral gastrin was released by an 
"oxyntopyloric reflex". Although possibly alkalinization of the antrum 
constitutes in itself a stimulus for gastrin secretion, a recent study 
in humans, wherein temporary antral alkalinization produced no increase 
in serum gastrin, would tend to refute this (56). 
3. Release of Gastrin by Contact with Food 
The component of normal diet primarily responsible for gastrin 
release is protein, which is most active after partial digestion to 
peptones, and still active as amino acids (110). Protein and other 
chemicals may act on the antral G-cell by direct stimulation of the 
microvilli on the luminal surface of the cell, or by neuronally mediated 
pathways such as those mediating the distention stimulus for gastrin 
release. 
4. Other Stimuli for Gastrin Release 
There are some other substances which effect a rise in serum 
gastrin for which a physiologic niche has not yet been found. Calcium 
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administered I.V. as the gluconate to normal subjects, increased serum 
gastrin 34% and doubled acid secretion (87), In duodenal ulcer patients, 
calcium increased gastrin 94% and acid fivefold. In patients with 
Zollinger-Ellison syndrome, calcium increased gastrin 55%, an important 
finding in view of the association between Z-E and hyperparathyroidism. 
In a corollary study, the hormone calcitonin, given I.V. to normal 
subjects, greatly inhibited gastric secretion and the gastrin response 
to food (6). However, the physiologic role of calcium and calcitonin 
in gastric secretion is unknown. 
A second substance which increases serum gastrin is epinephrine. 
Stadil and Rehfeld (95) reported in 1973 that epinephrine, given I.V. to 
normal subjects (25-75 ng/kg), produced a prompt and brief rise in serum 
gastrin and in acid secretion which was blocked by prior administration 
of beta-adrenergic blocking agents. They observed that insulin hypo¬ 
glycemia, as used to test the completeness of vagotomy, caused epinephrine 
to rise forty times over basal levels, enough to cause gastrin release 
and acid secretion. 
Brandsborg et al (13) studied duodenal ulcer patients before and 
after vagotomy and confirmed these findings. In these patients, the 
degree of insulin hypoglycemia attained correlated significantly with 
increased plasma adrenalin, which correlated significantly with increased 
serum gastrin. In normal subjects, epinephrine infused to levels seen 
with hypoglycemia doubled serum gastrin. The authors noted the association 
between pheochromocytoma and elevated gastrins which fall after resection, 




D. Inhibition of Gastrin Release 
The secretion of gastric juice by the stomach is inhibited by 
the presence in the duodenum of acid, fat, or substances of high or 
low osmolarity. The hormones secretin and cholecystokinin-pancreozymin 
(CCK-PZ) have less inhibitory effect (93). 
The physiologic mechanisms for inhibiting the release of gastrin 
are related, but incompletely understood. 
In 1954, Woodward and coworkers showed that acid in the stomach 
was a potent inhibitor of gastrin release in dogs (114). Later, Csendes 
and coworkers showed that, in Pavlov and antral pouch dogs, antral 
acidification with 0.1 N HC1 supressed gastrin response to insulin (21). 
Antral acidification has since been shown to inhibit gastrin release in 
response to most stimulants in dogs: vagal (insulin, sham-feeding, 
electrical), topical (protein, acetylcholine), and distention (18). 
In man results are less uniform. Fasting gastrin levels in normal 
subjects have been reported unchanged (18) and significantly decreased (39) 
by temporary antral acidification. Serum gastrin in normal subjects and 
duodenal ulcer patients has been reported unchanged (65) and significantly 
increased (18) after an acidified protein meal. One consideration is that 
the pH equated with acidification has varied from 5.5 to 1.0 in these 
studies. Inhibition of gastrin release is thought to occur most reliably 
at a pH of 1.5 or lower (110). 
Gastrin release is also inhibited by the gastrointestinal hormones 
secretin, glucagon, and, most recently, GIP (gastrointestinal inhibitory 
peptide) and VIP (vasoactive intestinal peptide), a group sharing other 
properties in common. 
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In 1902, Bayliss and Starling showed that acid in the duodenum 
caused release of secretin; in 1904, Sokolov showed that acid in the 
duodenum inhibited acid secretion. In 1957, Dragstedt and coworkers (43) 
found that intravenous secretin inhibits the gastric secretion stimulated 
by food. In 1973, Thompson and coworkers (103), studying normal subjects 
and patients with duodenal ulcer, found that intravenous secretin suppressed 
release of gastrin in response to food. When given to patients with 
Zollinger-Ellison syndrome, secretin dramatically increases serum gastrin, 
a finding previously reported as a case study by Isenberg and coworkers 
in 1972 (60). 
Glucagon has a parallel effect on gastrin. The Thompson group, 
studying normal subjects and patients with duodenal ulcer, found that 
intravenous glucagon depresses both basal serum gastrin and the gastrin 
response to a standard meal. Again, in patients with Zol1inger-El1ison 
syndrome, glucagon increased basal serum gastrin and did not impair 
gastrin response to food (7). 
Recent studies (108) have indicated that, given I.V. to Heidenhain 
pouch dogs, GIP and VIP do not alter basal serum gastrin but suppress the 
gastrin response to food. Calcitonin, as mentioned earlier, also suppresses 
release of gastrin. 
The import of these observations is not yet established, but the 
possibility that any of these agents functions in the physiologic 
regulation of gastrin release and gastric secretion remains open. 
E. Deactivation of Gastrin 
Circulating gastrin has a disappearance half-life of approximately 
eight minutes, less for the G17 fraction, more for G34. It is deactivated 
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or extracted from the blood primarily by the kidney, and to a lesser 
extent by the small bowel and secreting gastric fundus. Little is known 
about how gastrin is broken down; intact gastrin is not excreted in the 
urine to a significant extent (104). 
F. Actions of Gastrin 
The primary action of gastrin, which led to its isolation, is 
stimulation of the parietal cell of the gastric fundus to secrete acid, 
and facilitation of the parietal cell response to vagal stimulation. 
Gastrin, however, is prodigal in its actions, although in some it may 
not be physiologically important. (Actions of Gastrin, Table 2). 
The trophic effect of gastrin on gastric and duodenal mucosa 
and on pancreas, and probably on small bowel and colon mucosa as well, 
is independent of its secretory effect (63). The trophic response is 
mediated by synthesis of RNA, protein, and DNA; continued administration 
of pentagastrin is followed by mitosis and eventually by hyperplasia of 
gastrointestinal mucosal cells both in vitro and in vivo (63). In 
extreme degree, the hypergastrinemia of Zollinger-Ellison syndrome 
produces fundic hypertrophy evidenced as the large gastric folds seen 
on barium study. 
The relationship between gastrin and lower esophageal sphincter (LES) 
pressure attracted much attention in an effort to clarify the dysfunction 
in esophageal reflux. In 1972, Lipschutz and coworkers (74), studying 
opposums because the LES resembles man's, found that gastrin antiserum 
markedly reduced resting LES pressure and LES response to gastrin. Human 
studies again revealed conflicting data. In fasting normal subjects, serum 
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gastrin did not correlate with LES pressure (24). In two studies, fasting 
gastrins in patients with reflux, in comparison with controls, were found 
to be significantly lower (73), and not significantly different (37). 
Infusion of pentagastrin in normal subjects for an hour produced only 
modest increases in LES pressure (39). Lipschutz (73) found that 
alkalinization of the stomach in controls increased serum gastrin sig¬ 
nificantly and increased LES pressure 118%, but in reflux patients did 
not raise gastrin significantly and increased LES pressure only 35%. 
Farrell and McGuigan (37), studying patients with reflux and controls, 
found that acidification of the stomach caused gastrin and LES pressure 
to fall, while alkalinization caused both to rise, in both groups. They 
observed also that the reflux patients released significantly less 
gastrin in response to food, and reacted to pentagastrin with significantly 
less LES pressure increase, than did controls. It appeared to these 
authors that the LES abnormality in reflux comprised both reduced release 
of gastrin, and reduced LES responsiveness to gastrin. Higgs and coworkers (56), 
studying normal subjects, confirmed the pattern of LES response to acid and 
alkali in the stomach, but found no rise in gastrin with al kal i ni zation, 
and concluded that gastrin has no regulatory effect on LES pressure. 
G. Hypergastrinemia 
Our ability to identify clinical disorders of gastrin release and 
gastric secretion is still, unfortunately, ahead of our understanding of 
the normal mechanisms governing these processes. 
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Walsh and Grossman (110,111) have recently reviewed the hyper- 
gastrinemic disorders. Hypergastrinemia is seen in the absence of 
hypersecretion in 1) atrophic gastritis, particularly with circulating 
parietal cell antibodies and achlorhydria (pernicious anemia); 
2) gastric carcinoma (77), particularly affecting the body of the 
stomach; 3) pheochromocytoma; 4) vitiligo (58); and, rarely, other 
conditions. 
Hypergastrinemia with hypersecretion is recognized clinically as 
the Zol1inger-El1ison syndrome, first described in 1955 (117). In 
this syndrome, an autonomous non-beta-cell tumor of the pancreas produces 
gastrin, resulting in chronic hypergastrinemia, massive secretion of 
gastric juice, and intractable peptic ulceration, sometimes accompanied 
by diarrhea and steatorrhea (59,111). The tumors are often small, often 
metastasize, and contain high concentrations of tissue gastrin. Serum 
gastrins are commonly over 200 pg/ml; G34 predominates (88,89). 
The differential diagnosis of increased serum gastrin and excess 
acid secretion includes antral G-cell hyperplasia, isolated retained 
antrum, gastric outlet obstruction, short bowel syndrome (98) and chronic 
renal failure. Antral G-cell hyperplasia stands intermediate between 
Zol1inger-El1ison syndrome and peptic ulcer disease, with increased 
fasting gastrin, basal acid hypersecretion, and markedly increased 
gastrin response to food, seen in duodenal ulcer disease but not in 
Zol1inger-El1ison syndrome (41,83,111). No evidence for gastrinoma is 
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found, but profound hyperplasia of antral G-cells is seen by immuno¬ 
fluorescence. These patients do not respond to calcium or secretin 
challenge with a rise in gastrin, as do patients with Zol1inger-Ellison 
syndrome (99). The criteria for diagnosis of this condition have not 
been determined, and so its incidence is not known. Its relationship 
to Zol1inger-El1ison syndrome and to the more usual forms of peptic 
ulcer disease remains to be clarified. 
Hypergastrinemia in isolated retained antrum is thought to be due 
to gastrin release by the antral cuff, no longer inhibited by gastric 
acidification. In gastric outlet obstruction elevated gastrins are 
ascribed to distention of the stomach and to food stasis. In short 
bowel syndrome, and in chronic renal failure, gastrin catabolism may be 
impaired, resulting in some degree of hypergastrinemia. 
H. Gastrin in Peptic Ulcer Disease 
In his 1943 paper on vagotomy for duodenal ulcer, Dragstedt 
reported his observation that patients with duodenal ulcer secrete 
excess gastric juice at night and in response to food, histamine, or 
alcohol (29). This basal hypersecretion was ascribed to increased vagal 
stimulation, and it diminished after vagotomy. Still the etiology of 
ulcer disease has not been fully elucidated, and the role of gastrin 
remains uncertain. 
Patients with duodenal ulcer have the same quantity of antral 
G-cells as controls (83A), the same gastrin concentration in the antral 
mucosa (111), but an increased parietal cell mass (111), possibly in 

17 
response to the trophic effect of gastrin. Basal serum gastrin levels 
in patients with duodenal ulcer, when compared to controls, have been 
reported to be not significantly different (110), lower (51), and higher (9). 
Patients with duodenal ulcer appear to be more sensitive than controls 
to stimulation of gastrin release and acid secretion with pentagastrin (111), 
histamine, and calcium. They secrete acid at a significantly faster rate 
than do controls (106). In view of these findings, Yalow and Berson (9) 
theorized that in duodenal ulcer there is a failure of feedback inhibition 
of gastric secretion in the face of a high acid secretory rate, and that 
the "normal" gastrin levels reflect autonomous release of gastrin from 
the antrum. The circulating gastrin in duodenal ulcer patients has 
not been fractionated, but if this theory were true, a larger proportion 
of it would be expected to be G17, the most active component, rather than 
big-big gastrin, the inactive form which usually predominates in the 
fasting state. 
III. Histamine 
Histamine was originally synthesized as a chemical curiosity in 
1907. In 1911, Dale and Laidlaw identified the action of histamine on 
blood pressure, smooth muscle, and lymph flow. In 1920, Popielski was 
probably the first to discover that histamine stimulated gastric secretion. 
In 1927, Best, Dale and others determined that histamine was a natural 
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constitutent of the body, and its role in mediating the inflammatory 
response was soon documented. (See Structure, Table 1). 
In the early 1940's, Code and coworkers (19,109), verified the 
gastric secretory action of histamine in a series of experiments in 
which chronic histamine stimulation produced gastric and duodenal 
ulcers in animals. The histamine was administered in doses of 15-60 mg. 
given I.M. in a beeswax and mineral oil mixture for prolonged release. 
This preparation produced increased secretion of gastric juice in 
fifteen minutes which continued for up to 24 hours, and as long as 
52 hours. Daily injections produced erosions or ulcers in all animals 
in four days' to four weeks' time. Code seemed fascinated with this 
system and employed it successfully to produce ulcers in dogs, cats, 
guinea pigs, chickens, ducks, pigs, calves, monkeys, rabbits, and 
woodchucks (20,53,107). 
The physiologic role of histamine in gastric secretion is still 
debated, but current speculation favors the notion that histamine 
functions as a local transmitter and not as a gastric hormone (5,72). 
It is stored in gastric mucosa. Stimuli for acid secretion, including 
pentagastrin, cholinergic agents, insulin hypoglycemia, food, and 
distention, mobilize histamine, provoke histamine release in the gastric 
juice, and increase histamine metabolism (72). Histamine is thought to 
be stored near the parietal cells, and to act on them directly upon its 
release. Parietal cells also contain large amounts of histidine 
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decarboxylase, the enzyme which converts histidine to histamine, and 
may be activated during gastric secretion (72). Conceivably, histamine 
may not directly stimulate acid secretion, but may act to regulate 
gastric mucosal metabolism (62). 
A. Histamine Blockade 
Stimulation of smooth muscle contraction in gut and bronchi by 
histamine is blocked by mepyramine and other conventional antihistaminics (3). 
The receptors involved in these mepyramine-sensitive responses are defined 
as histamine-1 or HI-receptors. The action of histamine to stimulate 
acid secretion, increase the heart rate, and inhibit contractions in rat 
uterus is not deterred by conventional antihistamine blockade (3). 
In 1972, Black and associates (11) announced the synthesis of 
a compound, burimamide, which blocked these latter actions of histamine 
selectively. The receptors involved in these responses were defined as 
H-2 receptors, and the new class of drugs was called H2-receptor antagonist. 
The new compounds were chemical modifications of the histamine imidazole 
ring, with a thiourea side chain added. The antagonism of histamine by 
burimamide was competitive and specific, without significant interaction 
with histamine HI-receptors, catecholamine beta-receptors, or acetylcholine 
(muscarinic) receptors. 
Burimamide inhibits both histamine- and pentagastrin-stimulated 
acid secretion by 80% in humans (11). However, the drug is inactive 
orally, causes release of catechols (2), and has the troublesome side 
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effect of vomiting in dogs (57). It was soon superseded by metiamide, 
an H2-antagonist which is well absorbed, active when taken orally, 
without immediate side effects or catechol-releasing properties, and a 
fivefold more potent inhibitor of acid secretion than burimamide (2,52). 
(See Structure, Table 1). 
In researching the mechanism of action of metiamide, Code and 
Dousa (25) found that, in guinea pig acid-secreting fundic mucosa, 
metiamide blocked the stimulation of adenylate cyclase by histamine and 
its active derivatives, preventing increased formation of cAMP in response 
to histamine. Metiamide in high concentrations has also been found to 
block the uptake and metabolism of histamine by mouse cells in vitro (34). 
Burimamide prevents the release of histamine from mast cells in response 
to histamine stimulation (71). 
The studies of metiamide have revealed information about the 
distribution and function of H2-receptors in the cardiovascular system. 
Metiamide blocks histamine-stimulated increase in heart rate (1,35), 
decrease in blood pressure (1), and vasodilatation in peripheral blood 
vessels (44) and in gastric mucosa (5). Konturek and associates (68) 
documented the marked reduction in blood flow which accompanies the 
inhibitory action of metiamide on acid secretion in response to several 
stimuli. Albinus (2) confirmed this, and suggested that histamine may 
regulate gastric mucosal microcirculation during acid secretion, and that 
metiamide blocks this function. Others (17,72) feel the decreased mucosal 
blood flow is secondary to the inhibition of gastric secretion. 
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1. Effect on Gastric Secretion-Animal Studies 
The effect of metiamide on gastric secretion was first 
evaluated in animal studies which provided a wealth of information. 
Given in the absence of secretory stimulation to dogs (42) and cats (52), 
metiamide exerted no significant influence. When secretion was stimulated, 
metiamide proved a powerful inhibitor. 
Grossman and Konturek (48) gave metiamide I.V. to dogs with 
gastric fistulae and Heidenhain pouches, and found it inhibited gastric 
secretion during stimulation by histamine, pentagastrin, 2-deoxy-glucose, 
and liver extract. Atropine blocked the response to all but histamine, 
but in other studies has blocked response to histamine as well (48). 
Konturek and Rehfeld (68) reproduced these findings using histamine, 
pentagastrin, urecholine, and peptone meal as stimulants. Magee (78) 
reproduced them using histamine, pentagastrin, 2-deoxy-glucose, pilocarpine 
and food. Gibson and Hirschowitz (42) found that, given I.V. to dogs as 
a background, metiamide inhibited acid secretion in response to histamine, 
pentagastrin, 2-deoxy-glucose, and urecholine. Werner and Carter (113), 
studying gastric fistula dogs, reported that metiamide, given as a bolus, 
drip, or orally, decreased acid output in response to insulin infusion. 
Konturek and coworkers (66) studying gastric fistula cats, 
found that metiamide inhibited the acid response to histamine by 70%, to 
pentagastrin by 55%, to cerulein (an analogue of CCK) by 75%, to peptone 
meal by 95%, and to urecholine 100%; though the latter was only a weak 
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stimulant of gastric secretion, the others approximated the effectiveness 
of histamine. In an effort to explain these results, Konturek proposed 
that the parietal cell has separate receptors for histamine, gastrin, 
and acetylcholine, and that blockade of one receptor changes the 
properties of one or both of the other two receptors. He also suggested 
that the degree of interaction need not be the same in both directions, 
i.e., that blocking the histamine receptor might moderately inhibit 
the acetylcholine receptor, while blocking the acetylcholine receptor 
might only weakly inhibit the histamine receptor. Although recognizing 
that the histamine blocking activity of metiamide might not in the end 
prove to be the property which causes it to inhibit non-histamine stimulants 
of gastric secretion, Konturek concluded that the evidence suggested a 
physiologic role for histamine in gastric secretion, either as a final 
common mediator, as Code has maintained, or as an agent that sets the 
responsiveness of the parietal cell to other stimulants, in keeping with 
the multiple-receptor model. 
In contrast with acid secretion, pepsin secretion in response to 
cholinergic and secretin stimulation is actually augmented by metiamide (42,78). 
Magee (78) found further that pepsin secretion in response to histamine was 




Metiamide has a disappearance half-life of l%-2 hours, and most 
animal studies have examined its action over a few hours. However, 
Konturek (67) studied the effect on gastric fistula cats of histamine 
or pentagastrin given I.V. for 36 hours, alone or with metiamide. All 
animals (24) that received either stimulant alone developed duodenal 
ulcers, ten with perforation or hemorrhage. When metiamide was given 
I.V. as well, much smaller ulcers developed in 1 of 12 cats receiving 
histamine, and 3 of 12 receiving pentagastrin. Atropine prevented 
ulcers in half the animals so treated. Metiamide had no effect on 
pancreatic bicarbonate secretion stimulated by exogenous secretin or 
duodenal acidification. 
2. Effect on Gastric Secretion-Studies in Man 
Because the drug is under experimental controls, studies of 
metiamide in humans are few; those done corroborate the findings in 
animals. 
Carter and coworkers (16,17) produced acid secretion with 
intravenous insulin in 6 normal subjects and 4 patients with duodenal 
ulcer; metiamide 250 mg. was then given I.V. over 75 minutes. The 
drug produced a marked reduction in volume and acid concentration of 
gastric juice, with mean peak acid production in the last hour reduced 
by 70% in controls and 76% in ulcer patients compared to baseline. 

24 
Isenberg and coworkers (79) studied 17 patients with duodenal ulcer, 
and reported that 1) metiamide in doses of 100,200 or 300 mg. orally 
significantly inhibited acid secretion; 2) 200 or 300 mg. decreased acid 
secretion by more than 80%; and 3) 300 mg. decreased peptone-stimulated 
acid secretion by more than 80%. Acid inhibition correlated better with 
peak blood level than with ingested dose. No change in serum gastrin 
was observed. Barbezat (4), studying 9 subjects with duodenal ulcer, 
found that metiamide 200 mg. decreased pentagastrin-stimulated gastric 
secretion by 51%. 
Milton-Thompson (80) reported that 11 patients with duodenal 
ulcer, metiamide 400 mg. orally on retiring produced profound inhibition 
of nocturnal acid secretion in 10. Eight became anacidic for 1-6 hours 
after taking the drug. pH rose significantly, to well outside the 
maximum pH range for pepsin, and remained elevated for six hours. Serum 
gastrin was unchanged. 
Pounder and Mi 1ton-Thompson (85) assessed the clinical efficacy 
of metiamide in a double-blind study, placing 30 symptomatic duodenal 
ulcer patients on metiamide (200 mg. tid and 400 mg. hs), or on placebo, 
for 5-8 weeks. Those on metiamide had less daytime pain; night pain and 
antacid consumption were significantly decreased. Twelve of fifteen on 
metiamide were pain-free in the last three weeks of the trial. 
3. Additive Effect of Blocking Agents 
The interdependency of histamine and acetylcholine, and of 
histamine and gastrin, has been documented (72). The capacity of metiamide 
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or atropine alone to inhibit secretion in response to the major stimuli 
is described above. Recently the interaction of blocking agents in 
combination has come under study. In a study of 16 peptic ulcer patients, 
Thjodleifsson (101) reported that atropine augmented and prolonged the 
action of metiamide in inhibiting basal and pentagastrin-stimulated 
acid secretion in duodenal ulcer patients. 
Richardson and Walsh (90) reported that in 7 duodenal ulcer 
patients, metiamide 300 mg. with an anticholinergic drug, isopropamide, 
was more effective in suppressing food-stimulated acid secretion than 
was either drug alone. Metiamide alone inhibited acid secretion after 
a steak meal by 80%; metiamide with a maximum tolerated dose of 
isopropamide reduced acid secretion to less than 4.8 mEq/hr for 3 hours 
after the meal. There was no significant effect on serum gastrin or in 
gastric emptying with either drug or with the combination. They 
concluded that the effects of the two blocking agents were additive. 
Thompson and Reed (105) have concurred that the effect of metiamide and 
atropine on gastric secretion is additive. 
B. Toxicity of Metiamide 
The toxicity of metiamide was first manifested in 1974 in animal 
studies when three dogs receiving 81 mg/kg/day developed granulocytopenia 
and agranulocytosis with fewer than 500 white cells/mm (15). The blood 
dyscrasia proved reversible on withdrawal. Studies in humans were undertaken 
with careful monitoring of hematologic and other parameters. 
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In 1975, Forrest and coworkers (38) reported their experience 
with two patients taking metiamide who had developed neutropenia, 
heralded by sore throat, malaise and fever, one after metiamide 
1200 mg/day for 30 days with 1500 white cells, the other after 800 mg/day 
for 99 days with 700 white cells. The drug was stopped; both patients 
recovered clinically within ten days, with gradual hematologic recovery 
completed in a month. Metiamide was suspended from further clinical 
trials and permitted for use only in patients with intractable ulcer 
disease not amenable to any other modes of therapy. 
The toxicity of metiamide has been attributed to its thiourea 
side chain, which bears structural resemblance to some of the anti¬ 
neoplastic chemotherapeutic agents of known hematologic and bone 
marrow toxicity. 
C. Recent Uses of Metiamide 
Metiamide has recently found use in the emergent and long-term 
therapy of the Zol 1 inger-El 1 ison syndrome. 
In early 1975, Halloway and coworkers (50) reported a case in 
which a patient with previous partial gastrectomy and gastrojejunostomy 
for duodenal ulcer developed a perforated gastrojejunocolic fistula. 
After neogastrojejunostomy a high-output enterocutaneous fistula 
developed (6 ltr/24 hr), leading to severe, intractable alkalosis, while 
diagnosis of Zol1inger-Ellison syndrome was confirmed by gastrin 
assay (=1100). Metiamide, approved for emergent use by FDA, produced 
immediate improvement in blood chemistries, with complete stabilization 
and decreased fistula output in 36 hours, permitting successful total 
gastrectomy to be performed. 
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Richardson and Walsh (91) have treated three patients with 
Zollinger-El1ison syndrome, in whom gastrectomy was not an option, 
with metiamide (200-300 mg.) alone and with anticholinergics for up 
to 6 months. Metiamide alone effectively decreased acid secretion; 
metiamide with an anticholinergic produced near-total inhibition of 
acid secretion (2.4-0.1 mEq/30 min) lasting up to four hours. The 
patients' clinical status improved, with rare episodes of ulcer pain, 
decreased diarrhea and steatorrhea, no bleeding episodes, and weight 
gain in all cases. No hematologic disturbance was observed. 
D. New H2-Receptor Antagonist 
The newest H2-receptor antagonist is cimetidine (14), which lacks 
the thiourea side chain, and hopefully also the hematologic toxicity 
of metiamide. Cimetidine inhibits acid secretion in the basal state 
and in response to histamine, pentagastrin, and carbachol in dogs, and 
in response to histamine and pentagastrin in humans (14). In normal 
subjects, cimetidine, 200 mg. orally, inhibits food-stimulated acid 
secretion by 54-60% compared to placebo (84). Henn, Isenberg, and 
coworkers (54) studied 7 patients with duodenal ulcer treated with 
cimetidine 300 mg. orally. Basal secretion was essentially zero for 
five hours. Meal-stimulated secretion was inhibited 67%; inhibition 
correlated with peak blood cimetidine concentration. No effect on serum 
gastrin, and no toxic effect was observed. Clearly this group of 
compounds has promise for the therapy of ulcer disease. 
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THE PRESENT STUDY 
At the time this study was undertaken no reports of prolonged 
administration of H2-receptor antagonists in patients with Zollinger- 
Ellison syndrome were available. The effectiveness of metiamide in 
temporary inhibition of acid secretion had been amply documented, and 
the toxicity problem had become apparent. Our interest turned to 
cimetidine, which had recently been released for clinical trials; 
however, the drug was not available to us for research purposes, 
though metiamide could be readily obtained. 
It was decided to study the effectiveness of metiamide in 
preventing ulcers when endogenous hypergastrinemia and hypersecretion 
were produced by transplanting the antrum to the colon in dogs--an 
experimental model of Zollinger-El1ison syndrome. The procedure, 
originally devised by Dragstedt (28,30,31), involves gastro¬ 
jejunostomy to maintain continuity of the GI tract, and anastomosis 
of the isolated antrum to the transverse colon. The antral mucosa, 
stimulated by constant exposure to alkaline colonic contents, secretes 
gastrin continuously, producing hypergastrinemia and massive hypersecretion. 
Large, progressive ulcers form at the margin of the gastrojejunostomy in 
3-12 weeks postoperatively in 85% of animals so treated. The gastrin 
circulating in excess is endogenously secreted and in this the pre¬ 
paration uniquely resembles the Zol1inger-El1ison syndrome. The capacity 
of metiamide to prevent ulceration in this condition, or to halt or 
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reverse the progression of ulcers already formed, would clarify the 
potential of H2-receptor antagonists for use in the treatment of 
ulcer disease, particularly in the Zol1inger-El1ison syndrome. 
(Design of Study with Cross-Over, Table 3). 
I. Materials and Methods 
A. Procedure 
The antral-transplant procedure was performed in fourteen mongrel 
dogs. The dogs were anesthetized with 25 rng/kg of pentobarbital, and 
maintained on a Harvard respirator. Through a midline incision, the 
upper abdomen was exposed. The pylorus was divided, and each end over¬ 
sewn in three layers. Demartel clamps were placed across the junction 
of the middle and lower thirds of the stomach, and the stomach divided. 
A loop of small bowel was brought up to the stomach, and a point was 
chosen for the anastomosis approximately nine inches from the ligament 
of Treitz. An antecolic isoperistaltic gastrojejunostomy was performed 
in the Polya manner, using an inner layer of continuous chromic catgut 
and a seromuscular layer of inverting silk. 
The transverse colon was brought up to the distal antral segment 
and a segment of transverse colon was isolated between rubber-shod clamps. 
The antral pouch was anastomosed to the colon using the same two layer 
technique as above. 
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The abdominal cavity was irrigated with saline, hemostasis attained 
and the abdominal wall closed in layers with chromic catgut and silk. 
A collodion dressing was applied. Dogs were allowed to recover from 
anesthesia and were returned to routine laboratory care. (Completed 
Procedure, Figure 1). 
B. Gastrin Levels 
Preoperative serum gastrin levels were drawn on all dogs, and 
postoperative gastrins were drawn on dogs at nine and fourteen weeks 
postoperatively. 
The gastrin levels were prepared as follows: Dogs were fasted 
overnight. In the morning, two blood samples were drawn 15 minutes 
apart, kept at room temperature for 30 minutes, refrigerated at 6 degrees 
Fahrenheit for one hour, centrifuged at 39 degrees Fahrenheit for 
twenty minutes at 3000 rpm. The serum was drawn off and frozen at 
-20 degrees Fahrenheit. 
The gastrin assays were done by Upjohn Laboratories. 
C. Metiamide Preparation 
Metiamide was supplied by Smith, Kline and French Laboratories. 
Starting on the first postoperative day, the dogs in the control 
group were given placebo injections, and those in the drug group were 
given injections of metiamide daily. 
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The preparation of metiamide in a form suitable to our purposes 
was an endeavor of some magnitude. The drug has a biological half-life 
of 1^-2 hours (SK&F, Information for Investigators). In previous studies 
in animals and man it was given as a single oral dose, I.V. bolus or I.V. 
drip; people had received oral metiamide (TID and hs) for weeks. Our 
problem was to maintain effective blood levels constantly over a period 
of weeks to months in dogs. As the oral and intravenous routes were not 
feasible, we considered the possibility of intramuscular injections of 
the drug in a depot vehicle, as is used in Depo-Provera and other drugs. 
Inquiries revealed that depot vehicles are not standardized, but tailored 
to the medications involved. The Yale-New Haven Hospital Department of 
Pharmacy, while glad to help, pointed out that the pharmacokinetics 
of metiamide had been incompletely studied prior to withdrawal of the 
drug from clinical studies, and essential data on solubility and 
partition coefficients were too limited. A consult with University of 
Connecticut Professor of Pharmacy Dr. Charles Nightingale confirmed 
thi s. 
When efforts to develop a pharmacologically modern depot form 
were thus thwarted, attention was turned to the work of Code, who in 
1940 gave dogs injections of histamine in a mixture of beeswax and 
mineral oil, and found prolonged release producing gastric acid hyper¬ 
secretion starting in 15 minutes and lasting up to 52 hours. In view 
of the structural similarity of histamine and metiamide, it seemed 
conceivable that the same vehicle might work for us. With help from the 
Department of Pharmacy manufacturing personnel and others, Code's 
procedure was duplicated (20). 
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The beeswax-mineral oil mixture was prepared in batches. A 
ratio of one part beeswax to four parts mineral oil was used. 
Quantities were measured of beeswax, mineral oil (light weight, USP), 
and metiamide in powdered form, sufficient to result in injections of 
one cubic centimeter containing 500 mg. of metiamide. In the placebo 
injections, metiamide was omitted. The beeswax was melted in a glass 
beaker in a water bath at 100°C. The melting point of metiamide is 
148-152°C. The mineral oil was added and mixed in, then the metiamide. 
When homogeneous and while still molten, the mixture was drawn up 
into one-cc. plastic tuberculin syringes. Upon cooling to room 
temperature, the mixture forms a semi-solid mass, injectable through 
a 20 gauge needle. 
Code found that multiple small injections were less effective 
than two larger ones in releasing histamine evenly over long periods. 
Starting on the first postoperative day, dogs received single injections, 
in the hind thigh musculature, six days a week. 
D. Serum Metiamide Levels 
Serum metiamide levels were drawn on three dogs at 0,4,8, and 24 
hours after the initial metiamide injection, and at 3,5, and 7 days 
thereafter. Metiamide levels were also drawn on two dogs in the drug 
series after prolonged administration of metiamide. For each metiamide 
level, one blood sample was drawn, allowed to clot at room temperature, 
and the serum was drawn off and frozen. 
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Serum metiamide levels were assayed courtesy of Warren Randolph 
of Smith, Kline, and French Laboratories, Philadelphia, Pa. 
E. Endoscopy 
All dogs were followed for clinical signs of ulceration: weight 
loss, loss of appetite, blood in stools. When a question of ulcer 
arose, dogs were endoscoped. 
An ACMI 100-cm. single-lumen colonscope was loaned by the 
Department of Surgery at the West Haven Veteran's Administration 
Hospital for the endoscopy. Prior to endoscopy dogs were fasted 
overnight. Dogs were anesthetized with pentobarbital 25 mg/kg. 
The colonoscope was passed into the esophagus, past the gastroesophageal 
junction and into the stomach. The stomach was inflated with air. The 
fundus of the stomach was visualized, and the gastrojejunostomy stoma 
identified. The endoscope was advanced into the stomal orifice, into 
the opening of the efferent loop, and several centimeters down the 
efferent loop of the gastrojejunostomy, with air and water insufflation 
and suction as needed to maintain a good visualization. Throughout, 
the state of the fundic and jejunal mucosa was assessed, with particular 
attention paid to the jejunal mucosa directly opposite the stomal 
opening and for the first few centimeters down the efferent loop. Note 
was made of the location and extent of inflammation, erosion, ulceration, 
and bleeding of the mucosal surfaces. When endoscopic evaluation was 
complete, the stomach was emptied of air and the colonoscope was gradually 
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withdrawn. The dog was allowed to recover from anesthesia, and was 
returned to the protocol with routine laboratory care. 
F. Crossover 
Control dogs with endoscopically confirmed lesions were taken 
off placebo and crossed over to metiamide treatment. Dogs in the drug 
group were also endoscoped and crossed over, being taken off metiamide, 
placed on placebo, and carefully followed for development of ulcers. 
All dogs were given routine laboratory care and fed a stock laboratory 
diet. Dogs were followed until demise from perforation of ulcer, or 
other causes, occurred, whereupon postmortem examination was performed. 
II. Results 
A. Postoperative Mortality 
The dogs in the study underwent major surgery with little 
postoperative support. Postoperative mortality was defined arbitrarily 
as deaths occurring up to seven days postoperatively. In the practice 
series (7 dogs), and in the protocol series (14 dogs), postoperative 
mortality was the same, 43%. Postmortem examination was performed in 
all cases. Postoperative deaths were attributed to 1) considerations of 
technique, primary leaks of the gastrojejunal anastomosis, leading to 




B. Practice Series 
In order to develop adequate technical ability, preliminary 
experience with the procedure was obtained in a practice series of 
seven dogs. Postoperative mortality was 43% (3 dogs). Of four dogs 
surviving without complications of surgery, all four were found at 
endoscopy or at postmortem to have developed single or multiple 
marginal ulcers at the site of the gastrojejunal anastomosis. The 
ulcers were found on the jejunal side, opposite the anastomosis at 
the outlet of the stomach, and at distances up to approximately ten 
centimeters down the efferent loop. (See Figures 2 and 3). In this 
series, the mean length of time between operation and documentation 
of ulcers was 34 days (range, 9 to 74 days). 
C. Protocol Series 
1. Control Group 
In the control group of eight dogs, postoperative mortality 
was 25% (2 dogs). 
Twc other dogs died suddenly, without previous clinical 
signs of ulcer and therefore without endoscopy and crossover in medication. 
One of these died at seventeen days after the operation. At postmortem, 
this dog had a perforated ulcer of the jejunum opposite the gastrojejunostomy. 
The other dog died at ten days after operation. Postmortem examination 
in this dog revealed no reliable findings due to artifacts of freezing 
and autolysis; cause of death was not determined. Of note, in the 
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practice series, the shortest time between operation and perforation of 
ulcer was nine days, so it is possible that this dog had perforation 
at ten days postoperatively. 
Four dogs developed weight loss, loss of appetite, and weakness. 
These dogs were endoscoped. At endoscopy all four were found to have 
angry red, inflamed gastric mucosae, and severely inflamed, eroded, 
exudative and friable jejunal mucosae which bled easily. Three dogs 
had single or multiple jejunal ulcers, ranging in size from lxl cm to 
3x2 cm. The fourth dog had one large erosion opposite the stomal 
opening. Mean length of time from operation to documentation of ulcer 
was 18 days (range, 14-22 days). 
These four dogs were crossed over. Placebo injections were 
stopped, and injections of metiamide, 500 mg. daily, were begun. 
Little improvement in clinical status was observed. All four dogs 
eventually succumbed to perforation. Mean length of time between 
starting metiamide and death was 12.5 days (range, 7-17 days). 
Mean length of time between operation and demise in these four 
dogs was 31.25 days (range, 22-39 days). Mean weight loss between 
operation and endoscopy was 24% of preoperative body weight (range, 
20 to 26%). 
2. Drug Group 
In the drug group of six dogs, postoperative mortality was 
67% (4 dogs). 
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Two dogs surviving without complications of surgery were placed 
on metiamide 500 mg. INI daily starting directly postoperatively. These 
dogs survived for an extended period. One dog experienced minimal 
weight loss (6% of preoperative body weight); one, significant weight 
loss (51%). Both were endoscoped fourteen weeks after operation, at 
102 and 104 days postoperatively. At endoscopy each dog was found to 
have a single, small, superficial erosion of the jejunum, one opposite 
the anastomosis, and one a few centimeters down the efferent loop. 
The gastric and jejunal mucosaeotherwise appeared normal, blue-pink, 
moist and glistening, without inflammation, friability or bleeding. 
No ulcers were seen. 
These dogs were crossed over. Metiamide injections were stopped, 
and placebo injections begun. One dog (with 6% weight loss) died of 
perforated jejunal ulcer 10 days after stopping metiamide. The other dog 
is still alive and being followed; this dog has significant weight loss. 
D. Gastrin Levels 
The mean preoperative serum gastrin level for all dogs was 42.5 pg/ml, 
(range, 11 to 68 pg/ml). Normal range for the laboratory doing the assay 
is less than 120 pg/ml. Postoperatively serum gastrin rose to a mean of 
454.3 pg/ml, (range, 431 to 500 pg/ml). 
E. Metiamide Levels 
The assay for serum metiamide level revealed that detectable 
circulating levels of metiamide were not present in any of the samples. 

However, in dogs, metiamide may circulate in amounts which are effective 
in suppressing acid secretion but which are not detectable by the assay 
developed for the drug (see Discussion). 
III. Discussion 
A. Effectiveness of Procedure 
Our study reconfirmed the original findings of Dragstedt that 
transplantation of the antrum to the colon produces hypergastrinemia, 
hypersecretion and marginal ulceration at the site of the gastrojejunostomy 
Gastrin levels had not to our knowledge been done in connection with 
this procedure, and our data reveal that postoperatively serum gastrin 
ascends to the Zollinger-Ellison range (400-500 pg/ml), in keeping with 
the progressive nature of the ulcers produced. 
The ulcerogenic effectiveness of the procedure in our hands was 
comparable to the results reported earlier. Of those dogs surviving the 
postoperative hazards posed, all four of four in the practice series, 
all four of four in the control series, one (control) which perforated 
before crossover, and one of two in the drug series, all off metiamide, 
developed ulcers of the jejunal mucosa near the gastrojejunostomy. 
B. Metiamide Findings 
The report from Smith, Kline and French Laboratories that no 
detectable amount of metiamide was found in the serum samples according 
to their assay deserves some amplification. The SK&F Laboratory staff 
reports that amounts of metiamide which effectively inhibit gastric 
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secretion may circulate at levels too low to assay. For our purposes, 
this leaves two possibilities: 1) no metiamide was released from the 
beeswax vehicle, and none was circulating; or 2) the dogs had effective, 
but not detectable serum levels of metiamide. Thus, the amount of 
metiamide circulating is not known, though it must be less than the 
assay can detect; similarly, its effectiveness in suppressing acid 
secretion when given intramuscularly is not established. In retrospect, 
it appears that acid studies would be a useful adjunct in evaluating 
therapy with this drug-vehicle combination. We have based our conclusions 
regarding effectiveness of intramuscular metiamide on other data from 
the study. 
C. Control Group 
The control dogs in our study developed ulcers on placebo in an 
average of 18 days, with associated weight loss averaging 26% of 
preoperative body weight, lived an average of 12.5 days longer on 
metiamide, and died an average of 31 days after operation. 
These results can be explained by one of three hypotheses. 
One: metiamide as administered did not decrease acid secretion, and 
the progression of ulcers was unchecked. Acid studies were not done, 
and this cannot be verified. Two: metiamide did decrease acid secretion, 
and the dogs survived longer because of this. This also cannot be 
verified; one could not know how long an interval between ulceration 
and perforation to expect. The ulcers develop at widely varying rates; 
in the original study the length of time to perforation was 21-100 days. 
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in ours 9-74 days. In three dogs in this study (2 practice and 1 control) 
that went from operation to perforation without intervention, the average 
course was 33 days (range, 9-74 days). Although the pool is small, it 
does not seem that metiamide delayed perforation in the control dogs, 
however no case of healing of existing ulcer was observed. 
The third possibility is that metiamide did decrease acid 
secretion, but the ulcers, some massive, were far advanced, and in the 
face of severe weight loss, without other therapeutic or nutritional 
support, were unable to heal, and so went on to perforate. 
D. Drug Group 
The two dogs in our drug group developed no ulcers in 102 and 104 
days on metiamide, with weight loss of 51% and 6% respectively; after 
being taken off metiamide, one dog lived 10 days; the other is still 
being followed. 
These results might be explained by any of three hypotheses. 
The first is that metiamide had no effect, and the animals were just 
slow to develop ulcers. Several observations go against this. The 
length of time to perforation (114 days) is longer than any seen by 
Dragstedt, or elsewhere in our series. Although such a long interval 
is possible, it seems unlikely. The normal findings at endoscopy also 
go against this, although possibly an ulcer was missed which later 
perforated. Further, that this pattern should occur only in drug dogs 
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and in none of the controls is highly unlikely, although such small 
samples are not amenable to tests of statistical significance. 
The second hypothesis is that metiamide did inhibit gastric 
secretion, but the prolonged survival is due to other factors. In 
Dragstedt's series, 15% of dogs did not have ulcers at postmortem; 
the reasons for this were not clear. Some animals were sacrified, 
and not followed for maximal periods of time. In a study in which the 
antrum was transplanted with its vagal innervation preserved, ulcers 
did not develop; thus, vagal inhibitory influences may play a role 
under certain conditions (64). 
The third possibility is that metiamide decreased acid secretion, 
and this prolonged survival in the drug group dogs. The drug dogs 
lived more than three times longer than the controls and remained 
ulcer-free until taken off the drug. Off metiamide, ulcer appears at 
varying rates. The earliest documented ulcer in the practice series 
was at nine days; one drug dog off metiamide perforated at 10 days. 
The latest ulcer was at 74 days in our series, 100 days in Dragstedt's; 
the second drug dog, being followed, is within this range. 
The question of metiamide release from the vehicle is nagging. 
Code found that histamine given in the same manner produced increased 
gastric secretion within 15 minutes. Metiamide given intravenously has 
immediate effect; taken orally, the drug acts in 1-1^ hours (90,91). 
In our study, the dose of 500 mg. was ample, on a mg. per kg.-hr basis, 
to inhibit acid secretion for 24 hours in dogs, if it all reached the 
bloodstream. Therefore, we were dismayed to witness the downhill course 
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of the control dogs after cross-over; however, the advanced state of 
the ulcers may have been etiologic. The prolonged survival of the 
drug animals while on metiamide supports the contention that enough 
metiamide was released to keep acid secretion below the ulcerogenic 
level, providing effective prophylaxis against ulceration. 
IV. Conclusions 
Our study indicated that when metiamide was given IM in a beeswax 
vehicle to dogs with established hypergastrinemia and hypersecretion, 
with ulcer, it did not permit healing, and could not be shown to have 
effectively delayed progression of the ulcers to perforation. However, 
when the drug was started postoperatively, it appeared to confer 
protection against ulceration for up to 14 weeks in the face of significantly 
elevated gastrin levels. After discontinuing metiamide, ulcer developed 
at individual rates. 
These results are in keeping with most findings on metiamide. 
The only previous study of metiamide in hypergastrinemic animals was done 
by Konturek (67), who gave metiamide and pentagastrin intravenously for 
36 hours to gastric fistula cats. Pentagastrin given alone produced 
ulcers in 12 of 12 animals, five with perforation or hemorrhage. 
Pentagastrin given with metiamide produced smaller ulcers in 3 of 12 cats. 
Our results appear to corroborate this prophylactic effect of metiamide 
on ulcer formation. 
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In humans, because of experimental controls on its use, few 
studies of the effect of long-term metiamide therapy have been done. 
An oral regimen of metiamide has proven effective in reducing ulcer 
pain and antacid consumption in duodenal ulcer patients over eight 
weeks (85). Oral metiamide, with an anticholinergic, has also proven 
effective in the management of patients with the Zollinger-El1ison 
syndrome for up to six months, with marked inhibition of acid 
secretion, reduced ulcer pain, diarrhea, and steatorrhea, prevention 
of bleeding episodes, and weight gain (91). Given over extended periods, 
metiamide may block not only the acid secretory effect but also the 
trophic effect of gastrin on the parietal cell, producing a degree of 
parietal cell atrophy and diminished secretion on this basis as 
well. It would appear that patients on a regimen of oral metiamide 
experience some degree of ulcer healing, although this has not been 
documented. In our study daily metiamide IM did not permit ulcer healing. 
This represents either a problem of drug administration, resulting in 
incomplete inhibition of acid secretion, or a result of the advanced 
nature of ulcer disease in our control animals, which mandated more 
vigorous therapy for cure. 
The results of our work and that of others confirms that the 
H2-receptor antagonists promise much for therapy of gastric secretory 
disorders. Cimetidine, the H2~receptor antagonist currently under study, 
blocks acid secretion as well as metiamide, and may prove to be without 
serious side effects and toxicity. In that case the therapeutic potential 
of cimetidine and its future congeners is considerable, and these agents 




It seems sadly ironic for surgeons, who played an early, crucial, 
and ongoing role in advancing our understanding of gastric secretion and 
its disorders, to be now presented with most promising improvements in 
the medical treatment of ulcer disease. Yet it may be expected that, 
as before, a combination of medical and surgical care will optimally 
benefit the ulcer patient. In the case of metiamide, the recent observation 
that anticholinergics augment and prolong metiamide effectiveness is 
tempered by the problem of accompanying atropinic side effects. The 
anticholinergic effect desired might obtain from vagotomy, either truncal, 
selective, or proximal gastric. H2-receptor blockade might then provide 
maximal adjunctive therapy, being without known immediate side effects, 
with clinical advantage to the patient. The etiology and therapy of ulcer 
disease will continue to be studied and debated, hopefully with further 
benefit to people who suffer its manifestations. 

Figure 1 Antral Transplantation Procedure with Antrum-to-Colon 
Anastomosis and Gastrojejunostomy. 

Figure 2: Gross specimen from an animal that succumbed to multiple 
stomal ulcers, one of which had perforated, producing 
generalized peritonitis. 
Figure 3: Section through one edge of a perforating ulcer in the 
efferent 1tmb of a gastrojejunostomy. Note scarring 
and acute and chronic inflammation. 

TABLE 1 
STRUCTURES OF PARIETAL CELL AGONISTS: 
GASTRIN, ACETYLCHOLINE, HISTAMINE, and METIAMIDE 
GASTRIN (G17) Pyr- Gly- Pro- Trp- Leu- Glu- 
GIu- Glu- Glu- Glu- Ala- Try- 
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Metiamide, an H2-receptor antagonist, has been found to inhibit 
acid secretion in duodenal ulcer patients (4,16,17,79,80,85). In an 
effort to evaluate its possible use in treatment of the Zollinger-Ellison 
syndrome, the effect of prolonged administration of metiamide on 
formation of ulcers was studied in dogs with hypergastrinemia and hyper¬ 
secretion secondary to transplantation of the antrum to the colon, an 
ulcerogenic preparation devised by Dragstedt (28,30,31). Metiamide was 
given, 500 mg. IM daily, in a beeswax vehicle for prolonged release 
devised by Code (19,109). 
The antral transplant procedure was performed in 14 dogs. Post¬ 
operative mortality was 43%. Postoperative serum gastrin levels were 
elevated into the Zol1inger-Ellison range--400 to 500pg/ml. All four 
animals in the control group, on daily placebo injections, developed 
ulcers, confirmed endoscopically, an average of 18 days after operation. 
They were then "crossed-over" and placed on metiamide, lived an average of 
12.5 days longer, and succumbed to peritonitis secondary to perforated 
stomal ulcer. The two animals in the drug group, on daily metiamide 
injections, were ulcer-free by endoscopy done 102 and 104 days after 
operation. They were taken off drug and placed on placebo injections. 
One dog died of perforated stomal ulcer after 10 days on placebo. The 
other is still being followed (82 days on placebo). Serum metiamide levels 
were equivocal. 
It appears that metiamide does not promote healing of existing ulcers, 
but protects against ulcer formation in this preparation. Clinical 
usefulness of H2-receptor antagonists in therapy of Zol1inger-Ellison 
syndrome is discussed. 
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